Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
暂无分享,去创建一个
C. Paweletz | M. Kris | P. Jänne | S. Ou | Dong-Wan Kim | M. Nishio | I. Taylor | G. Oxnard | R. Martins | F. Dunphy | Hui Zhang | J. O'Connell | Z. Goldberg | T. Mok